[go: up one dir, main page]

AR110904A1 - ANTICUERPOS ANTI-TGF-b Y SU USO - Google Patents

ANTICUERPOS ANTI-TGF-b Y SU USO

Info

Publication number
AR110904A1
AR110904A1 ARP180100118A ARP180100118A AR110904A1 AR 110904 A1 AR110904 A1 AR 110904A1 AR P180100118 A ARP180100118 A AR P180100118A AR P180100118 A ARP180100118 A AR P180100118A AR 110904 A1 AR110904 A1 AR 110904A1
Authority
AR
Argentina
Prior art keywords
tgf
antibody
seq
conditions
antibodies
Prior art date
Application number
ARP180100118A
Other languages
English (en)
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR110904A1 publication Critical patent/AR110904A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La solicitud proporciona un anticuerpo pan-TGF-b mejorado para el tratamiento de afecciones que están mediadas por TGF-b, incluyendo enfermedades autoinmunitarias, afecciones fibróticas, y cánceres. También se proporcionan usos y usos del anticuerpo junto con otros agentes inmunomoduladores tales como un anticuerpo anti-PD-1. Reivindicación 1: Un anticuerpo monoclonal aislado que se une específicamente a TGF-b1, TGF-b2, y TGF-b3 humano, que comprende las regiones determinantes de la complementariedad de cadena pesada (CDR) 1 - 3 de SEQ ID Nº 1 y las CDR1 - 3 de cadena ligera de SEQ ID Nº 2, en donde el anticuerpo comprende una región constante de IgG4 que tiene una prolina en la posición 228 (numeración UE).
ARP180100118A 2017-01-20 2018-01-18 ANTICUERPOS ANTI-TGF-b Y SU USO AR110904A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762448800P 2017-01-20 2017-01-20

Publications (1)

Publication Number Publication Date
AR110904A1 true AR110904A1 (es) 2019-05-15

Family

ID=66669189

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180100118A AR110904A1 (es) 2017-01-20 2018-01-18 ANTICUERPOS ANTI-TGF-b Y SU USO

Country Status (2)

Country Link
KR (3) KR102568885B1 (es)
AR (1) AR110904A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201701985YA (en) * 2013-03-20 2017-04-27 Genzyme Corp Methods for treating osteogenesis imperfecta
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
CN116327915A (zh) * 2015-04-03 2023-06-27 佐马技术有限公司 使用TGF-β抑制剂和PD-1抑制剂治疗癌症

Also Published As

Publication number Publication date
KR20230124768A (ko) 2023-08-25
KR102699080B1 (ko) 2024-08-27
KR20190105077A (ko) 2019-09-11
KR102568885B1 (ko) 2023-08-21
KR20240133763A (ko) 2024-09-04

Similar Documents

Publication Publication Date Title
PE20200734A1 (es) Anticuerpos anti-tgf-beta y su uso
CL2022000328A1 (es) Anticuerpo humanizado que se une específicamente al receptor de transferrina humano (tfr); composición farmacéutica; uso del anticuerpo humanizado para preparar un medicamento útil para tratar un trastorno neurológico. (divisional solicitud no. 3207-2017)
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
EA201991729A1 (ru) Антитела к tgf-бета и их применение
PE20191208A1 (es) Anticuerpos anti-cd73 y usos de los mismos
AR104213A1 (es) Anticuerpos anti-cd38 como agentes terapéuticos
MX374810B (es) Anticuerpos 4-1bb anti-humano y usos de los mismos
PE20190737A1 (es) Anticuerpos anti-cd27
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
PE20200384A1 (es) Metodo de fabricacion de anticuerpos bispecificos, anticuerpos bispecificos y uso terapeutico de dichos anticuerpos
ECSP17005649A (es) Anticuerpos anti-tau humanizados
AR101875A1 (es) Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas
MX2019013132A (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
UY36692A (es) Anticuerpos anti-cd40 y usos de los mismos
JOP20200177A1 (ar) طرق علاج السرطان باستخدام الأجسام المضادة anti-pd-1 المناهضة
PE20211887A1 (es) Receptor antigenico quimerico (car) que comprende un dominio de union a antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t
PE20161389A1 (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
EA202090800A1 (ru) Новые анти-cd3-эпсилон антитела
AR096601A1 (es) Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
CL2020002600A1 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
AR119507A1 (es) Anticuerpos triespecíficos anti-pd-1 / lag3 / tigit y anticuerpos biespecíficos anti-pd-1 / lag3
MX2020008122A (es) Anticuerpos anti-pd-1.
CL2022000230A1 (es) Anticuerpos anti-ms4a4a y métodos de uso de los mismos
EA201992460A1 (ru) Антитела-агонисты btla и их применение